-
Unraveling HLA Class I Expression in Breast Cancer: A Step Towards Precision Immunotherapy
At the San Antonio Breast Cancer Symposium 2024, Dr. Paula Ines Gonzalez Ericsson presented important research on HLA class I expression in breast cancer and its implications for immunotherapy response. Her…
-
Dr. Charles Geyer, Jr.’s Contributions to Advancing Triple-Negative Breast Cancer Research
At the San Antonio Breast Cancer Symposium 2024, Dr. Charles Geyer, Jr. presented important research focused on improving treatment strategies for triple-negative breast cancer (TNBC). His work continues to drive…
-
Maria Vittoria Dieci at SABCS 2024: Advancing Immunotherapy in TNBC
At the San Antonio Breast Cancer Symposium 2024, Maria Vittoria Dieci presented key findings from the A-BRAVE trial, shedding light on the role of avelumab in high-risk triple-negative breast cancer…
-
CheckMate 649: Five-Year Follow-Up Reinforces Nivolumab + Chemotherapy as Standard First-Line Treatment
The five-year follow-up data from CheckMate 649, presented at the 2025 ASCO Gastrointestinal Cancers Symposium, confirms the long-term survival benefits of nivolumab plus chemotherapy in advanced gastric, gastroesophageal junction, and…
-
Advancing First-Line Therapy for Unresectable Hepatocellular Carcinoma (uHCC): CheckMate 9DW Results
The phase 3 CheckMate 9DW trial, presented at ASCO24, brings promising results for nivolumab (NIVO) + ipilimumab (IPI) as a potential new standard of care in first-line treatment for unresectable…
-
Who Benefits Most from Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer?
A systematic review and meta-analysis, published in The Lancet Oncology, provides new insights into which patients benefit most from adding docetaxel to androgen deprivation therapy (ADT). The data, pooled from…
-
Sequential CD20 CAR-T Therapy is Superior to Salvage Chemotherapy in B-cell Lymphoma Patients with CD19 CAR-T Treatment Failure
In recent years, with the application of CD19 CAR-T in refractory/relapsed B-cell lymphoma, we have encountered patients for whom CD19 CAR-T treatment is ineffective or those who relapse after a brief period of effectiveness. Beyond exploring factors that may affect the efficacy of CD19 CAR-T therapy, many doctors and researchers are actively seeking effective treatments…
Connecting Medical Expertise through Media
